Literature DB >> 15837213

Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus.

Douglas S Reed1, Cathleen M Lind, Matthew G Lackemeyer, Lawrence J Sullivan, William D Pratt, Michael D Parker.   

Abstract

Two live, attenuated strains of Venezuelan equine encephalitis virus (VEE), IE1150K and V3526, were administered to macaques to determine if they could elicit protection against an aerosol challenge with virulent VEE virus of the IE variety (VEEV-IE). These viruses were rescued from full-length cDNA clones of 68U201 (VEEV-IE variety) and Trinidad donkey (VEEV-IA/B variety), respectively, and both have a furin cleavage site deletion mutation and a second-site resuscitating mutation. Both vaccines elicited neutralizing antibodies to viruses of the homologous variety but not to viruses of the heterologous variety. Eight weeks after vaccination, the macaques were challenged by aerosol exposure to virulent 68U201. Macaques vaccinated with V3526 were protected as well as macaques inoculated with IE1009, the wild-type infectious clone of 68U201. However, IE1150K failed to significantly protect macaques relative to controls. V3526 has now been shown to protect macaques against both IA/B [Pratt WD, Davis NL, Johnston RE, Smith JF. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models. Vaccine 2003;21(25-26):3854-62] and IE strains of VEE viruses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837213     DOI: 10.1016/j.vaccine.2004.12.023

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  34 in total

1.  Antibody to the E3 glycoprotein protects mice against lethal venezuelan equine encephalitis virus infection.

Authors:  Michael D Parker; Marilyn J Buckley; Vanessa R Melanson; Pamela J Glass; David Norwood; Mary Kate Hart
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages.

Authors:  Karine Labadie; Thibaut Larcher; Christophe Joubert; Abdelkrim Mannioui; Benoit Delache; Patricia Brochard; Lydie Guigand; Laurence Dubreil; Pierre Lebon; Bernard Verrier; Xavier de Lamballerie; Andreas Suhrbier; Yan Cherel; Roger Le Grand; Pierre Roques
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

3.  Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Authors:  Farooq Nasar; Demetrius Matassov; Robert L Seymour; Theresa Latham; Rodion V Gorchakov; Rebecca M Nowak; Grace Leal; Stefan Hamm; John H Eldridge; Robert B Tesh; David K Clarke; Scott C Weaver
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

4.  Novel Insect-Specific Eilat Virus-Based Chimeric Vaccine Candidates Provide Durable, Mono- and Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Authors:  Jesse H Erasmus; Robert L Seymour; Jason T Kaelber; Dal Y Kim; Grace Leal; Michael B Sherman; Ilya Frolov; Wah Chiu; Scott C Weaver; Farooq Nasar
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

5.  Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose.

Authors:  Chad J Roy; A Paige Adams; Eryu Wang; Kenneth Plante; Rodion Gorchakov; Robert L Seymour; Heather Vinet-Oliphant; Scott C Weaver
Journal:  J Infect Dis       Date:  2014-01-07       Impact factor: 5.226

6.  Identification of a surrogate marker for infection in the African green monkey model of inhalation anthrax.

Authors:  Cynthia A Rossi; Melanie Ulrich; Sarah Norris; Douglas S Reed; Louise M Pitt; Elizabeth K Leffel
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

7.  Comparison of Aerosol- and Percutaneous-acquired Venezuelan Equine Encephalitis in Humans and Nonhuman Primates for Suitability in Predicting Clinical Efficacy under the Animal Rule.

Authors:  Janice M Rusnak; Lesley C Dupuy; Nancy A Niemuth; Andrew M Glenn; Lucy A Ward
Journal:  Comp Med       Date:  2018-10-03       Impact factor: 0.982

Review 8.  Vaccines for Venezuelan equine encephalitis.

Authors:  Slobodan Paessler; Scott C Weaver
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

Review 9.  Chikungunya virus and prospects for a vaccine.

Authors:  Scott C Weaver; Jorge E Osorio; Jill A Livengood; Rubing Chen; Dan T Stinchcomb
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

10.  Improved efficacy of a gene optimised adenovirus-based vaccine for venezuelan equine encephalitis virus.

Authors:  Amanda J Williams; Lyn M O'Brien; Robert J Phillpotts; Stuart D Perkins
Journal:  Virol J       Date:  2009-07-31       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.